HSC-Derived Fatty Acid Oxidation in Steady-State and Stressed Hematopoiesis
The broad definition of metabolism is the sum of biochemical processes that generate or consume energy in a living organism. This is a vast amount: more than 8,700 reactions and 16,000 metabolites [1]. Pathways utilizing abundant nutrients, such as carbohydrates, fatty acids (FAs), and amino acids, are the basis of core metabolism and are vital for energy homeostasis. Cells utilize these nutrients for energy in the form of adenosine triphosphate (ATP), primarily generated by aerobic respiration using glucose as the metabolite [2]. (Source: Experimental Hematology)
Source: Experimental Hematology - October 9, 2022 Category: Hematology Authors: Jayna J. Mistry, Kristian Bowles, Stuart A. Rushworth Tags: Review Source Type: research
HSC derived fatty acid oxidation in steady state and stressed haematopoiesis
The broad definition of metabolism is the sum of the biochemical processes that generate or consume energy in a living organism. This is a vast amount: more than 8,700 reactions and 16,000 metabolites [1]. Pathways utilising abundant nutrients such as carbohydrates, fatty acids and amino acids are the basis of core metabolism and vital for energy homeostasis. Cells utilise these nutrients for energy in the form of ATP, primarily generated by aerobic respiration using glucose as the metabolite [2]. (Source: Experimental Hematology)
Source: Experimental Hematology - October 9, 2022 Category: Hematology Authors: Jayna J Mistry, Kristian Bowles, Stuart A Rushworth Tags: Review Source Type: research
TBL1X: At the Crossroads of Transcriptional and Posttranscriptional Regulation
Located on the X chromosome, the TBL1X gene was first identified in 1999 when its deletion was discovered to be associated with an X-linked human hearing defect, ocular albinism with sensorineural deafness (OASD) [1]. Additional TBL1 family members have since been identified and include TBL1X-related 1 (TBL1XR1) located on chromosome 3 and TBL1Y, the Y-linked homolog of TBL1X [2]. These genes encode for a family of highly evolutionarily conserved proteins sharing high structural and functional similarities from yeast to humans. (Source: Experimental Hematology)
Source: Experimental Hematology - October 4, 2022 Category: Hematology Authors: Betsy A. Pray, Youssef Youssef, Lapo Alinari Tags: Perspective Source Type: research
Tbl1x: at the crossroads of transcriptional and post-transcriptional regulation
Located on the X chromosome, the TBL1X gene was first identified in 1999 when its deletion was discovered to be associated with an X-linked human hearing defect, ocular albinism with sensorineural deafness (OASD) 1. Additional TBL1 family members have since been identified and include TBL1X-related 1 (TBL1XR1) located on chromosome 3 and TBL1Y, the Y-linked homologue of TBL1X 2. These genes encode for a family of highly evolutionarily conserved proteins sharing high structural and functional similarities from yeast to human. (Source: Experimental Hematology)
Source: Experimental Hematology - October 4, 2022 Category: Hematology Authors: Betsy A Pray, Youssef Youssef, Lapo Alinari Tags: Perspective Source Type: research
Cover 2: Editorial Board
(Source: Experimental Hematology)
Source: Experimental Hematology - September 30, 2022 Category: Hematology Source Type: research
Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model
Myelofibrosis (MF) is the most severe of Philadelphia chromosome –negative myeloproliferative neoplasms (MPN). The complex phenotype of patients with MF includes fibrosis and hematopoietic failure in bone marrow (BM), stem/progenitor cell mobilization, and development of extramedullary hematopoiesis with splenomegaly, and their clinical course is associated wit h an increased risk of thrombosis, bleeding, and evolution to acute leukemia [1–4]. MF may be driven by gain of function mutations in several genes of the thrombopoietin axes, such as MPL, the thrombopoietin receptor; JAK2, the first element of the MPL signaling...
Source: Experimental Hematology - September 30, 2022 Category: Hematology Authors: Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Mario Falchi, Antonio di Virgilio, Giuseppe Sarli, Celine Wilke, Andreas Bruederle, Anirudh Prahallad, Francesca Arciprete, Maria Zingariello, Anna Rita Migliaccio Tags: Article Source Type: research
Preclinical studies on the use of a P-selectin blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model
Myelofibrosis (MF) is the most severe of Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The complex phenotype of the MF patients includes fibrosis and hematopoietic failure in bone marrow (BM), stem/progenitor cell mobilization, development of extramedullary hematopoiesis with splenomegaly and their clinical course is associated with increased risk of thrombosis, bleeding and evolution to acute leukemia (1 –4). MF may be driven by gain of function mutations in several genes of the thrombopoietin axes such as MPL, the thrombopoietin receptor, JAK2, the first element of the MPL signaling, and calretic...
Source: Experimental Hematology - September 30, 2022 Category: Hematology Authors: Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Mario Falchi, Antonio di Virgilio, Giuseppe Sarli, Celine Wilke, Andreas Bruederle, Anirudh Prahallad, Francesca Arciprete, Maria Zingariello, Anna Rita Migliaccio Source Type: research
Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12
Diffuse large B-cell lymphoma (DLBCL) is an essentially heterogeneous subgroup of aggressive B-cell lymphomas. To categorize the entity based on the “cell-of-origin” (COO), gene expression profiling studies have classified DLBCL into three subtypes with different clinical outcomes: the activated B-cell-like (ABC) subtype, the germinal center B-cell-like (GCB) subtype, and an unclassified subtype [1, 2]. Patients with ABC-DLBCL exhibit a rela tively refractory clinical course compared to others when treated with the standard regimen, rituximab-CHOP [1, 2]. (Source: Experimental Hematology)
Source: Experimental Hematology - September 30, 2022 Category: Hematology Authors: Toshikage NAGAO, Kota YOSHIFUJI, Daichi SADATO, Yotaro MOTOMURA, Makiko SAITO, Kurara YAMAMOTO, Kouhei YAMAMOTO, Ayako NOGAMI Source Type: research
Role of ASXL1 in Hematopoiesis and Myeloid Diseases
Mammalian ASXL family genes (ASXL1, ASXL2 and ASXL3) are the mammalian homologs of Drosophila Additional sex combs Asx (1). Asx deletion leads to a homeotic phenotype characteristic of both Polycomb group (PcG, repressive complex associated with H3K27me3) and Trithorax group (TrxG, activating function associated with H3K4me3) gene deletions (1-3). Both Asxl1 and Asxl2 expression is virtually ubiquitous throughout embryogenesis and in adult tissues, whereas Asxl3 expression is more restricted and only detectable in lymph node, eye, lung, skin, brain, and pituitary gland (4). (Source: Experimental Hematology)
Source: Experimental Hematology - September 29, 2022 Category: Hematology Authors: Xin Gao, Xiaona You, Nathalie Droin, Lauren G Banaszak, Jane Churpek, Eric Padron, Klaus Geissler, Eric Solary, Mrinal M. Patnaik, Jing Zhang Tags: Review Source Type: research
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are heterogeneous myeloid neoplastic disorders characterized by ineffective hematopoiesis leading to cytopenias and an increased risk of progression and transformation to acute myeloid leukemia (AML)1. The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been shown to improve the natural history of patients with MDS and CMML2 and remain standard therapies in the treatment of MDS3. However, a majority of patients experience primary HMA failure (no response or progression during treatment) or secondary failure (relapse after i...
Source: Experimental Hematology - September 20, 2022 Category: Hematology Authors: Faezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, Pamela Lockyer, Guillermo Montalban-Bravo, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Caleb Class, Irene Ganan-Gomez, Kim-Anh Do, Guillermo Garcia-Manero, Yue Source Type: research
Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, a clonal malignancy, identified by a translocation of chromosomes 9 and 22 forming a constitutively active tyrosine kinase fusion protein, BCR-AB [1,2]. The leukemia stem cells (LSCs) in CML share phenotypic hematopoietic stem cell properties [3 –5]. CML is treated primarily with tyrosine kinase inhibitors (TKIs) that eliminate the bulk of the disease; however, these fail to eradicate LSCs, leading to disease relapse or progression to a more aggressive blast phase leukemia [6–9]. (Source: Experimental Hematology)
Source: Experimental Hematology - September 14, 2022 Category: Hematology Authors: Sweta B. Patel, Valeriya Kuznetsova, Victoria R. Matkins, Alana M. Franceski, Mahmoud A. Bassal, Robert S. Welner Source Type: research
Ex vivo expansion of phenotypic and transcriptomic CML stem cells
We believe that our work is appropriate for your journal for the following reasons: (Source: Experimental Hematology)
Source: Experimental Hematology - September 14, 2022 Category: Hematology Authors: Sweta B. Patel, Valeriya Kuznetsova, Victoria R. Matkins, Alana M Franceski, Mahmoud A. Bassal, Robert S. Welner Tags: Article Source Type: research
CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries. CLL is characterized by the clonal expansion of small mature CD5+CD23+ lymphocytes in the peripheral blood (PB), lymphoid organs, and bone marrow (BM) [1]. During CLL development, genomic changes occur in B cells that lead to altered apoptosis and survival pathways [2,3]. One of the underlying mechanisms driving CLL is the accumulation of malignant B cells that have escaped apoptosis [1,4]. The BM and lymphonodular microenvironment is composed of immune cells and stromal cells that enhance CLL cell survival through the pr...
Source: Experimental Hematology - September 9, 2022 Category: Hematology Authors: Tharshika Thavayogarajah, Dzmitry Sinitski, Omar El Bounkari, Laura Torres-Garcia, Hadas Lewinsky, Alexander Harjung, Hong-Ru Chen, Jens Panse, Lucia Vankann, Idit Shachar, J ürgen Bernhagen, Steffen Koschmieder Tags: ARTICLE Source Type: research
CXCR4 and CD74 together enhance cell survival in response to migration-inhibitory factor in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries. CLL is characterized by the clonal expansion of small mature CD5+CD23+ lymphocytes in the peripheral blood (PB), lymphoid organs, and bone marrow (BM) [1]. During CLL development, genomic changes occur in B cells that lead to altered apoptosis and survival pathways [2,3]. One of the underlying mechanisms driving CLL is the accumulation of malignant B cells that have escaped apoptosis [1,4]. The BM and lymphonodular microenvironment is composed of immune cells and stromal cells that enhance CLL cell survival through the pr...
Source: Experimental Hematology - September 9, 2022 Category: Hematology Authors: Tharshika Thavayogarajah, Dzmitry Sinitski, Omar El Bounkari, Laura Torres-Garcia, Hadas Lewinsky, Alexander Harjung, Hong-Ru Chen, Jens Panse, Lucia Vankann, Idit Shachar, J ürgen Bernhagen, Steffen Koschmieder Tags: ARTICLE Source Type: research
CXCR4 and CD74 together enhance cell survival in response to MIF in CLL
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries. CLL is characterized by the clonal expansion of small mature CD5+CD23+ lymphocytes in the peripheral blood (PB), lymphoid organs, and bone marrow (BM)1. During CLL development, genomic changes occur in B cells that lead to altered apoptosis and survival pathways2,3. One of the underlying mechanisms driving CLL is the accumulation of malignant B cells that have escaped apoptosis1,4. The BM and lymphonodular microenvironment is composed of immune cells and stromal cells that enhance CLL cell survival through the production ...
Source: Experimental Hematology - September 9, 2022 Category: Hematology Authors: Tharshika Thavayogarajah, Dzmitry Sinitski, Omar El Bounkari, Laura Torres-Garcia, Hadas Lewinsky, Alexander Harjung, Hong-Ru Chen, Jens Panse, Lucia Vankann, Idit Shachar, J ürgen Bernhagen, Steffen Koschmieder Tags: Article Source Type: research
